Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 292, Issue 6, 2007, Pages

  Liu, Li Fen ^a   Purushotham, Aparna ^a   Wendel, Angela A ^a   Belury, Martha A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DESATURASE; ADIPOCYTOKINE; CD36 ANTIGEN; CHLORDANE; CONJUGATED LINOLEIC ACID; FATTY ACID SYNTHASE; LIPOPROTEIN LIPASE; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; ROSIGLITAZONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; ENZYME REPRESSION; FATTY LIVER; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPODYSTROPHY; MACROPHAGE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; WEIGHT GAIN;

ADIPOCYTES; ADIPONECTIN; ADIPOSE TISSUE; ADIPOSITY; ANIMALS; APOPTOSIS; BODY WEIGHT; DIETARY FATS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FATTY LIVER; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEPTIN; LINOLEIC ACIDS, CONJUGATED; LIPID METABOLISM; LIPOPROTEINS, VLDL; LIVER; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; OBESITY; RNA, MESSENGER; THIAZOLIDINEDIONES; TIME FACTORS; TRIGLYCERIDES;

EID: 34447499065     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00523.2006     Document Type: Article

References (49)

1. Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia 42: 1033-1049, 1999.
2. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 53: 409-435, 2002.
3. Boden G, Homko C, Mozzoli M, Showe LC, Nichols C, Cheung P. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 54: 880-885, 2005.
4. Bradbury MW. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am J Physiol Gastrointest Liver Physiol 290: G194-G198, 2006.
5. Brown JM, Boysen MS, Chung S, Fabiyi O, Morrison RF, Mandrup S, McIntosh MK. Conjugated linoleic acid induces human adipocyte delipidation: autocrine/paracrine regulation of MEK/ERK signaling by adipocytokines. J Biol Chem 279: 26735-26747, 2004.
6. Brown JM, Boysen MS, Jensen SS, Morrison RF, Storkson J, Lea-Currie R, Pariza M, Mandrup S, McIntosh MK. Isomer-specific regulation of metabolism and PPARγ signaling by CLA in human preadipocytes. J Lipid Res 44: 1287-1300, 2003.
7. Carmona MC, Louche K, Nibbelink M, Prunet B, Bross A, Desbazeille M, Dacquet C, Renard P, Casteilla L, Penicaud L. Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice. Int J Obes 29: 864-871, 2005.
8. Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, Soukas AA, Sharma R, Hudgins LC, Ntambi JM, Friedman JM. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 297: 240-243, 2002.
9. Degrace P, Demizieux L, Gresti J, Chardigny JM, Sebedio JL, Clouet P. Hepatic steatosis is not due to impaired fatty acid oxidation capacities in C57BL/6J mice fed the conjugated trans-10,cis-12-isomer of linoleic acid. J Nutr 134: 861-867 , 2004.
10. DeLany JP, Blohm F, Truett AA, Scimeca JA, West DB. Conjugated linoleic acid rapidly reduces body fat content in mice without affecting energy intake. Am J Physiol Regul Integr Comp Physiol 276: R1172-R1179, 1999.
11. DeLany JP, West DB. Changes in body composition with conjugated linoleic acid. J Am Coll Nutr 19: 487S-493S, 2000.
12. Evans M, Brown J, McIntosh M. Isomer-specific effects of conjugated linoleic acid (CLA) on adiposity and lipid metabolism. J Nutr Biochem 13: acid. J Nutr 134: 508-516 , 2002.
13. Gaullier JM, Halse J, Hoye K, Kristiansen K, Fagertun H, Vik H, Gudmundsen O. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans. J Nutr 135: 778-784, 2005.
14. Gutierrez-Juarez R, Pocai A, Mulas C, Ono H, Bhanot S, Monia BP, Rossetti L. Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. J Clin Invest 116: 1686-1695, 2006.
15. Henry RR. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. Clin Ther 25: B47-B63, 2003.
16. Ide T. Interaction of fish oil and conjugated linoleic acid in affecting hepatic activity of lipogenic enzymes and gene expression in liver and adipose tissue. Diabetes 54: 412-423, 2005.
17. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52: 1655-1663, 2003.
18. Javadi M, Beynen AC, Hovenier R, Lankhorst AE, Lemmens AG, Terpstra AHM, Geelen MJH. Prolonged feeding of mice with conjugated linoleic acid increases hepatic fatty acid synthesis relative to oxidation. J Nutr Biochem 15: 680-687, 2004.
19. Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab 19: 547-566, 2005.
20. Kang K, Miyazaki M, Ntambi JM, Pariza MW. Evidence that the anti-obesity effect of conjugated linoleic acid is independent of effects on stearoyl-CoA desaturase1 expression and enzyme activity. Biochem Biophys Res Commun 315: 532-537, 2004.
21. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54: 117-121, 2005.
22. Ko SH, Song KH, Ahn YB, Yoo SJ, Son HS, Yoon KH, Cha BY, Lee KW, Son HY, Kang SK. The effect of rosiglitazone on serum lipoprotein (a) levels in Korean patients with type 2 diabetes mellitus. Metabolism 52: 731-734, 2003.
23. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917-923, 2003.
24. Miyazaki M, Kim YC, Gray-Keller MP, Attie AD, Ntambi JM. The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. J Biol Chem 275: 30132-30138, 2000.
25. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 44: 2210-2219, 2001.
26. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 286: 1195-1200, 2001.
27. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414: 821-827, 2001.
28. Moloney F, Yeow TP, Mullen A, Nolan JJ, Roche HM. Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus. Am J Clin Nutr 80: 887-895, 2004.
29. Moya-Camarena SY, Heuvel JPV, Blanchard SG, Leesnitzer LA, Belury MA. Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARα. J Lipid Res 40: 1426-1433, 1999.
30. Musso G, Gambino R, Durazzo M, Biroli G, Carello M, Faga E, Pacini G, De Michieli F, Rabbione L, Premoli A, Cassader M, Pagano G. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 42: 1175-1183, 2005.
31. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35: 367-372, 2002.
32. Peters Harmel AL, Kendall DM, Buse JB, Boyle PJ, Marchetti A, Lau H. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Curr Med Res Opin 20: 215-223, 2004.
33. Poirier H, Niot I, Clement L, Guerre-Millo M, Besnard P. Development of conjugated linoleic acid (CLA)-mediated lipoatrophic syndrome in the mouse. Biochimie 87: 73-79, 2005.
34. Poirier H, Rouault C, Clement L, Niot I, Monnot MC, Guerre-Millo M, Besnard P. Hyperinsulinaemia triggered by dietary conjugated linoleic acid is associated with a decrease in leptin and adiponectin plasma levels and pancreatic beta cell hyperplasia in the mouse. Diabetologia 48: 1059-1065, 2005.
35. Poirier H, Shapiro JS, Kim RJ, Lazar MA. Nutritional supplementation with trans-10, cis-12-conjugated linoleic acid induces inflammation of white adipose tissue. Diabetes 55: 1634-1641, 2006.
36. Purushotham A, Wendel AA, Liu LF, Belury MA. Maintenance of adiponectin attenuates insulin resistance induced by dietary conjugated linoleic acid in mice. J Lipid Res 2006.
37. Reddy JK, Sambasiva Rao M. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 290: G852-G858, 2006.
38. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 116: 1793-1801, 2006.
39. Takahashi Y, Kushiro M, Shinohara K, Ide T. Activity and mRNA levels of enzymes involved in hepatic fatty acid synthesis and oxidation in mice fed conjugated linoleic acid. Biochim Biophys Acta 1631: 265-273, 2003.
40. Terpstra AH, Javadi M, Beynen AC, Kocsis S, Lankhorst AE, Lemmens AG, Mohede IC. Dietary conjugated linoleic acids as free fatty acids and triacylglycerols similarly affect body composition and energy balance in mice. J Nutr 133: 3181-3186, 2003.
41. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53: 2169-2176, 2004.
42. Tsuboyama-Kasaoka N, Takahashi M, Tanemura K, Kim HJ, Tange T, Okuyama H, Kasai M, Ikemoto S, Ezaki O. Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice. Diabetes 49: 1534-1542, 2000.
43. Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T. Peroxisome proliferator-activated receptor (PPAR)α activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARα, PPARγ, and their combination. Diabetes 54: 3358-3370, 2005.
44. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808, 2003.
45. Wellen KE, Hotamisligil GS. Inflammation, stress, diabetes. J Clin Invest 115: 1111-1119, 2005.
46. West DB, DeLany JP, Camet PM, Blohm F, Truett AA, Scimeca J. Effects of conjugated linoleic acid on body fat and energy metabolism in the mouse. Am J Physiol Regul Integr Comp Physiol 275: R667-R672, 1998.
47. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830, 2003.
48. Xu X, Storkson J, Kim S, Sugimoto K, Park Y, Pariza MW. Short-term intake of conjugated linoleic acid inhibits lipoprotein lipase and glucose metabolism but does not enhance lipolysis in mouse adipose tissue. J Nutr 133: 663-667, 2003.
49. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941-946, 2001.